Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.46 USD
Change Today +0.03 / 2.10%
Volume 31.9K
PLX On Other Exchanges
Tel Aviv
As of 6:40 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

protalix biotherapeutics inc (PLX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/13/14 - $3.00
52 Week Low
08/24/15 - $1.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

protalix biotherapeutics inc (PLX) Related Businessweek News

No Related Businessweek News Found

protalix biotherapeutics inc (PLX) Details

Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-106, an oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein; and PRX-112, an orally administered glucocerebrosidase enzyme (GCD) for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD produced and encapsulated within carrot cells. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.

234 Employees
Last Reported Date: 03/12/15
Founded in 1993

protalix biotherapeutics inc (PLX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $93.7K
Founder and Executive Vice President of Resea...
Total Annual Compensation: $395.5K
Chief Financial Officer, Vice President, Secr...
Total Annual Compensation: $524.1K
Chief Operating Officer
Total Annual Compensation: $283.7K
Senior Vice President of Product Development
Total Annual Compensation: $348.9K
Compensation as of Fiscal Year 2014.

protalix biotherapeutics inc (PLX) Key Developments

Protalix BioTherapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Protalix BioTherapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of USD 3.782 million compared to USD 2.425 million a year ago. Operating loss was USD 4.472 million compared to USD 5.447 million a year ago. Net loss for the period was USD 5.071 million compared to USD 6.119 million a year ago. Basic and diluted net loss per share was USD 0.05 compared to USD 0.07 a year ago. For the six months, the company reported revenues of USD 8.174 million compared to USD 9.121 million a year ago. Operating loss was USD 9.315 million compared to USD 11.915 million a year ago. Net loss for the period was USD 11.043 million compared to USD 13.464 million a year ago. Basic and diluted net loss per share was USD 0.12 compared to USD 0.15 a year ago.

Protalix Biotherapeutics, Inc. Reports Positive Phase I Clinical Study Results for PRX-106 Oral Anti-TNF

Protalix BioTherapeutics, Inc. announced positive clinical study results from the company's Phase I trial of PRX-106, an orally administered plant cell-expressed recombinant anti-TNF fusion protein. PRX-106 demonstrated a favorable safety and tolerability profile and biological activity in the gut. The Phase I trial is a randomized, parallel-design, open-label study designed to evaluate the safety and pharmacokinetics of PRX-106 in healthy volunteers. The trial enrolled 14 subjects that were randomized to one of three dosing cohorts receiving PRX-106 doses equivalent to 2mg, 8mg or 16mg Tumor Necrosis Factor receptor-Fc fusion protein. Subjects received once daily oral administrations for 5 consecutive days. The results demonstrated that oral administration of PRX-106 is safe and well tolerated. No major side effects were noted, and no suppression of the immune system was observed. Regulatory T cell activation showing biological activity in the gut was observed. Fluorescence-activated cell sorting analysis (FACS) was performed using various antibodies for surface markers, and it was observed that all three dosages of PRX-106 promoted the induction of various subsets of T cells, some of which are correlated with anti-inflammatory response. In preclinical studies evaluating oral PRX-106 the compound alleviated immune-mediated hepatitis and reduced interferon gamma levels in a concanavalin A immune mediated hepatitis mouse model. Additionally, oral administration of PRX-106 alleviated immune mediated colitis in a well-established mouse model, promoting serum levels of anti-inflammatory IL-10 and regulatory T-cells. Protalix is currently evaluating the best indication to take forward with PRX-106. The Company anticipates identifying this shortly and initiating a proof of concept trial in patients around year end.

Protalix BioTherapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 01:00 PM

Protalix BioTherapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 01:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Moshe Manor, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLX:US $1.46 USD +0.03

PLX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLX.
View Industry Companies

Industry Analysis


Industry Average

Valuation PLX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTALIX BIOTHERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at